Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Kidney Diseases × etelcalcetide hydrochloride × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Genitourinary 1

Conditions

Vascular Calcification 1 Neoplasm Metastasis 1 Kidney Diseases 1 Hyperparathyroidism 1 Chronic Kidney Disease-Mineral and Bone Disorder 1 Bone Diseases 1

Interventions

spartalizumab 1 pembrolizumab 1 etelcalcetide hydrochloride 1 aldesleukin 1 Sorafenib 1 Sodium Bicarbonate 1 Interleukin-2 1 Adalimumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03960437 2023-09-21

Parsabiv-MBD

Columbia University

Phase 2 Completed

22 enrolled 14 charts

GenitourinaryHead & Neck

Bone Diseases, Hyperparathyroidism, Kidney Diseases, Neoplasm Metastasis, Chronic Kidney Disease-Mineral and Bone Disorder, Vascular Calcification

Data powered by HemOnc (CC BY 4.0) Colophon ⚡